• No results found

To fail or not to fail : clinical trials in depression Sante, G.W.E.

N/A
N/A
Protected

Academic year: 2021

Share "To fail or not to fail : clinical trials in depression Sante, G.W.E."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

To fail or not to fail : clinical trials in depression

Sante, G.W.E.

Citation

Sante, G. W. E. (2008, September 10). To fail or not to fail : clinical trials in depression.

Retrieved from https://hdl.handle.net/1887/13091

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/13091

Note: To cite this publication please use the final published version (if applicable).

(2)

TO FAIL OR NOT TO FAIL - CLINICAL TRIALS IN DEPRESSION

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof.mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op woensdag 10 september 2008 klokke 13.45 uur

door

Gijs Willem Eduard Santen geboren te Groningen

in 1980

(3)

Promotiecommissie:

Promotor: Prof. dr. M. Danhof Co-promotor: Dr. O.E. Della Pasqua

Referent: Prof. dr. S.A. Montgomery, Imperial College, London, UK Overige leden: Prof. dr. A. de Boer, Universiteit van Utrecht

Prof. dr. A.F. Cohen Prof. dr. J. van der Greef Prof. dr. A.P. IJzerman Prof. dr. E.R. de Kloet Prof. dr. F.G. Zitman

(4)

"Although a man shall never be able to hit Stars by shooting at them,

yet he shall come much nearer to them, than another that throws at Apples."

Nehemiah Grew (1641-1712)

Aan mijn ouders Aan Nina

(5)

The research presented in this thesis was made possible by a Worlwide Development Fellowship for Post-graduate Training in Clinical Pharmacology and Discovery Medicine from GlaxoSmithKline and was performed at the Division of Pharmacology of the Leiden- Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands.

The printing of this thesis was financially supported by:

GlaxoSmithKline

J.E. Jurriaanse Stichting

Leiden-Amsterdam Center for Drug Research

Photo cover by Bo Gort (www.bogort.com) Typeset in LATEX

Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands ISBN 978-90-8559-377-5

©2008 Gijs Santen

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission of the author.

(6)

CONTENTS

SECTION I GENERAL INTRODUCTION 7

Chapter 1 Clinical trials in depression: Challenges and opportunities 9

Chapter 2 Scope and outline of the investigations 37

SECTION II CLINICAL ENDPOINTS 43

Chapter 3 Sensitivity of the individual items of the Hamilton depression rat- ing scale to response and its consequences for the assessment of

efficacy 45

Chapter 4 Comparative analysis of the sensitivity of the individual items of the Montgomery Asberg depression rating scale to response and

its consequences for the assessment of efficacy 61 Chapter 5 The missing link between clinical endpoint and pharmacological

receptor systems in depression 77

SECTION III DATA ANALYSIS 95

Chapter 6 Evaluation of treatment response in depression studies using a

Bayesian parametric cure rate model 97

Chapter 7 Heterogeneity in patient response in depression:

The relevance of functional data analysis 111

Chapter 8 Relevance of a new hierarchical model for the analysis of longitu-

dinal data with dropout in depression trials 127

SECTION IV CLINICAL TRIAL SIMULATION 145

Chapter 9 From trial and error to trial simulation: An appraisal of current

beliefs in clinical research practice in depression 147 Chapter 10 Information-based adaptive designs for the assessment of efficacy

of antidepressant drugs: A Bayesian framework for interim anal-

ysis accounting for enrolment rate 171

(7)

SECTION V CONCLUSIONS AND PERSPECTIVES 189 Chapter 11 To fail or not to fail - clinical trials in depression:

Summary, discussion and perspectives 191

Chapter 12 Nederlandse samenvatting (Synopsis in Dutch) 209

List of abbreviations 217

Nawoord 219

Curriculum Vitae 221

List of publications 223

Referenties

GERELATEERDE DOCUMENTEN

Taking current clinical practice as a starting point, seven factors have been identified for evaluation: (a) sample size (number of patients), (b) randomi- sation ratio across

Based on data from randomised, placebo controlled trials with paroxetine, a graphical analysis and a statistical analysis were performed to identify the items that are most sensitive

The aim of the current investigation was therefore to evaluate the sensitivity of individual items of the MADRS to response (irrespective of treatment type), followed by a comparison

Based on a dichotomisation of patients into responders or non-responders, two types of graphical representations were used to describe (1) the rate of response for each individual

Currently, the analysis of depression studies is based on the difference between placebo and active treatment at the end of the study (usually 6-12.. Evaluation of treatment response

The loadings, i.e., the deviations from the mean for each observation, of the first four principal components which emerged from the classical principal component analysis (SVD) of

LOCF has either reduced power or an inflated type I error, especially when dropout rates are unequal for active and placebo treatment and total dropout rate is high (as in study 2)..

Using his- torical clinical trial data, we evaluate in an integrated manner the impact of (a) sample size (number of patients), (b) randomisation ratio across treatment arms,